Jazz Pharmaceuticals (JAZZ) 2024 Wells Fargo Healthcare Conference summary

Business performance and strategic priorities

• Achieved record Q2 revenues over $1 billion, with 15% growth from key products and 10% oncology growth.

• Focus remains on diversified, growing revenue, advancing pipeline, and operational excellence.

• No longer providing specific Vision 2025 financial metrics, but core principles remain priorities.

• Investments are prioritized for long-term growth over near-term margin maximization.

• Emphasis on leveraging expertise in sleep, seizures, and oncology for future innovation.

R&D pipeline and clinical catalysts

• Zanidatamab shows best-in-class efficacy in second-line biliary tract cancer, with a PDUFA date set for November 29 and European submission underway.

• Upcoming key readout for frontline gastroesophageal adenocarcinoma expected in Q2 2025.

• Phase III breast cancer trial launched for patients progressed on or intolerant to HER2 therapies.

• Zepzelca frontline small cell lung cancer data expected by year-end, potentially expanding its use.

• Differentiated mechanism of zanidatamab includes receptor clustering, HER3 blockade, and potent immune effector function.

Market positioning and commercial strategy

• Strong enthusiasm from oncologists for zanidatamab's efficacy, safety, and ease of use, especially in community settings.

• Existing solid tumor commercial infrastructure will be leveraged for zanidatamab's launch.

• Zepzelca is the leading agent in second-line small cell lung cancer, with $1 billion cumulative sales and 15% YoY growth.

• IMforte trial could expand Zepzelca to frontline use, with readout expected by year-end.

• Rylaze continues to grow, with high pediatric utilization and efforts to expand into adolescent/young adult markets.